Back to CELG-RIView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
View Full LandscapeDrug Information
Target Indication
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Clinical Trial
NCT07221149Last updated: 3/6/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
FOLFOX orPhase 3
Colorectal Cancer
Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfaPhase 3
Breast Cancer
Atazanavir/ritonavir monotherapyPhase 3
HIV-1 Infection
Topical Dapsone 5% GelPhase 3
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
ONO-4538Phase 3
Non-Small Cell Lung Cancer
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts